MARKET

SELB

SELB

Selecta Biosci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7958
+0.0214
+2.76%
Closed 19:09 05/20 EDT
OPEN
0.8000
PREV CLOSE
0.7744
HIGH
0.8425
LOW
0.7550
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
5.28
52 WEEK LOW
0.6469
MARKET CAP
120.81M
P/E (TTM)
3.757
1D
5D
1M
3M
1Y
5Y
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and m...
GlobeNewswire · 5d ago
Executives Buy Around $1.5M Of 4 Penny Stocks
US stock futures traded lower this morning on Thursday ahead of the producer price index. Investors, meanwhile, focused on some notable insider trades.
Benzinga · 05/12 11:32
Could The Market Be Wrong About Selecta Biosciences, Inc. (NASDAQ:SELB) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Selecta Biosciences' (NASDAQ:SELB) recent performance, when its stock has...
Simply Wall St. · 05/10 19:23
Needham Maintains Buy Rating for Selecta Biosciences: Here's What You Need To Know
Needham has decided to maintain its Buy rating of Selecta Biosciences (NASDAQ:SELB) and lower its price target from $7.00 to $6.00. Shares of Selecta Biosciences are trading up 2.84% over the last 24 hours, at $0.83 per share.
Benzinga · 05/06 16:09
Recap: Selecta Biosciences Q1 Earnings
  Selecta Biosciences (NASDAQ:SELB) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:56
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 80.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:45
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
BRIEF-Selecta Biosciences Reports First Quarter 2022 Financial Results
reuters.com · 05/05 11:44
More
No Data
Learn about the latest financial forecast of SELB. Analyze the recent business situations of Selecta Biosci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SELB stock price target is 7.83 with a high estimate of 13.00 and a low estimate of 6.00.
High13.00
Average7.83
Low6.00
Current 0.7958
EPS
Actual
Estimate
-0.070.020.110.20
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 132
Institutional Holdings: 58.99M
% Owned: 38.86%
Shares Outstanding: 151.81M
TypeInstitutionsShares
Increased
27
4.49M
New
11
349.63K
Decreased
39
4.86M
Sold Out
17
953.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Carrie Cox
President/Chief Executive Officer/Director
Carsten Brunn
Chief Financial Officer
Kevin Tan
Chief Operating Officer/Senior Vice President
Lloyd Johnston
Chief Human Resource Officer
Kristen Baldwin
Chief Scientific Officer
Takashi Kishimoto
Other
Peter Traber
Independent Director
Goran Ando
Independent Director
Timothy Barabe
Independent Director
Nishan de Silva
Independent Director
Scott Myers
Independent Director
Aymeric Sallin
Independent Director
Timothy Springer
Independent Director
Patrick Zenner
No Data
No Data
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. It enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.